Another study of EGFR-mutant NSCLC patients administered first-generation EGFR-TKIs and upfront radiotherapy for both the primary and metastatic sites reported a significantly prolonged median PFS (20.2 vs. 12.5 months; p < 0.001) and OS (25.5 vs. 17.4 months; p < 0.001) compared with those without radiotherapy [88]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.